The complaint, filed in the U.S. District Court for the Central District of California, centers on a June 2025 FDA inspection of the company’s iLet Bionic Pancreas. Prosecutors allege that while management promoted the device’s performance, they withheld a Form 483 report citing over 18,000 unreported customer complaints. The company did not publicly acknowledge the inspection findings for four months, according to the filing.
In section Releases
Beta Bionics Faces Class Action Over Alleged Concealment of FDA Findings
Shareholders are targeting Beta Bionics, Inc. in a federal class action lawsuit, alleging the medical device company suppressed negative FDA inspection results and thousands of patient complaints. The litigation follows a sharp valuation collapse, with BBNX shares sliding from a January peak of $31.99 to under $9 by April 2026.
When the issues finally surfaced, management reportedly characterized the FDA’s findings as a disagreement over reporting definitions rather than a failure of device safety. This narrative faced scrutiny as subsequent disclosures—including an FDA Warning Letter detailing risks of life-threatening hypoglycemia—triggered investor exits. The stock lost roughly 72% of its value during the class period, which runs from July 30, 2025, to February 24, 2026. Investors seeking to serve as lead plaintiffs in the litigation have until November 3, 2026, to file with the court.
Comments (0)
No comments yet. Be the first!